Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
NCT ID: NCT00236041
Last Updated: 2014-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
38 participants
INTERVENTIONAL
2004-04-30
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
NCT00236093
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
NCT00236145
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
NCT00496392
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
NCT01842893
Safety of Fentanyl TAIFUN Treatment
NCT00822614
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The secondary objectives are:
* to evaluate the characteristics of BTP in children with pain, including their response to treatment
* to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children with regard to time to adequate analgesia by utilizing a stop watch to measure the time for each unit of study drug in the double blind phase
* to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children by assessing the occurrence of inadequate analgesia as assessed by the use of rescue medication
* to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children by assessing the numbers of patients who withdraw from the study because of inadequate analgesia
* to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these children by assessing the duration of analgesic effect by using the FPS-R administered at approximately 30, 45, and 60 minutes after the start of each unit of study drug after an optimal dosage is obtained
* to determine the distribution of optimal doses of ACTIQ treatment for these children by age group (3 to under 6 years, 6 to under 11 years, and 11 to under 16 years)
* to establish a safe and effective titration scheme for ACTIQ in these children during the open label phase
* to evaluate the safety of ACTIQ treatment for these children through the assessment of adverse events, clinical laboratory assessments (serum chemistry and hematology), vital sign measurements (including blood pressure, heart rate, and respiration rate), hemoglobin-oxygen saturation level (SpO2, measured via pulse oximetry), electrocardiograms (ECGs), physical examinations, and level of sedation (measured by the University of Michigan Sedation Scale \[UMSS\])
* to characterize the pharmacokinetics profile of ACTIQ (fentanyl citrate) in these children
* to investigate the exposure and efficacy relationship between plasma concentration of fentanyl and clinical measures of analgesia
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACTIQ®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The child is aged 3 to under 16 years and weighs at least 15 kg.
3. The child must be using ATC opioid therapy for pain associated with cancer and be opioid-tolerant. NOTE: This requirement is defined as the patient receiving at least 1 mg/kg/day or 40 mg/day or more of oral morphine (or an equi-analgesic dosage of another opioid) or at least 25 mcg/hour of transdermal fentanyl for at least 7 days, (ATC opioid therapy may be administered as patient-controlled analgesia \[PCA\]).
4. The child must be experiencing episodes of BTP (defined as a transient flare of pain that requires a bolus of medication as treatment) as follows:
1. patients with cancer must be experiencing an average of at least 1 BTP episode a day.
2. patients with non-cancer related pain must be experiencing an average of 2 BTP episodes a day.
5. The child has an average daily pain score of 6 or less (of 10) on the FPS-R.
6. Girls who are postmenarche or sexually active must have a negative urine pregnancy test prior to the baseline visit, must be using a medically acceptable method of birth control, and must agree to continue use of this method for the duration of the study (and for 30 days after participation in the study). Acceptable methods of birth control include: barrier method with spermicide; steroidal contraceptive (eg, oral, transdermal, implanted, or injected) in conjunction with a barrier method; intrauterine device (IUD); or abstinence.
7. The child, in the opinion of the investigator, is able to administer ACTIQ treatment effectively (ie, adequately moving the unit around in the mouth and sucking, not biting, the unit).
8. The child must be an inpatient.
Exclusion Criteria
2. The child has known or suspected hypersensitivities/allergies or other contraindications to any ACTIQ component.
3. The child has received monoamine oxidase inhibitors (MAOIs) within 14 days before the first ACTIQ treatment.
4. The child has moderate to severe oral mucositis.
5. The child has a neuromuscular disease, significant renal impairment, or significant hepatic impairment as determined by the investigator.
6. The child has any other medical condition or is receiving concomitant medication/therapy that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise data collection.
7. The child has received any experimental drug/therapy within 14 days of the first ACTIQ treatment. NOTE: Children may not be participating concurrently in another study when the other study requires experimental drug therapy.
8. A child's exacerbations of pain are only associated with medical procedures (such as radiation therapy, wound dressing, and bone marrow aspiration).
9. The child is receiving any other treatment that, in the opinion of the investigator, could interfere with the pain response.
10. For a female patient of childbearing potential: is pregnant or lactating. (Any female patient becoming pregnant during the study will be withdrawn from the study.)
11. The child has, in the opinion of the investigator, developmental delay that would interfere with the use of ACTIQ therapy.
3 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cephalon
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Messina, Pharm D
Role: STUDY_DIRECTOR
Cephalon, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital of Arkansas
Little Rock, Arkansas, United States
UCLA Pediatric Pain Program
Los Angeles, California, United States
Childrens Hospital of Orange
Orange, California, United States
Lucille Packard Childrens Hospital
Palo Alto, California, United States
Connecticut Childrens Medical Center
Hartford, Connecticut, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
Nemours Childrens Clinic
Jacksonville, Florida, United States
St. Joseph's Children's Hospital
Tampa, Florida, United States
Scottish Rite Children's Medical Center
Atlanta, Georgia, United States
Kapi'olani Medical Center
Honolulu, Hawaii, United States
Children's Memorial Center
Chicago, Illinois, United States
Children's Memorial Hospital
Chicago, Illinois, United States
University Hospitals of Iowa
Iowa City, Iowa, United States
Cardinal Glennon Children's Hospital
St Louis, Missouri, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
University of New Mexico
Albuquerque, New Mexico, United States
SUNY Upstate Medical University
Syracuse, New York, United States
Children's Hospital at Montefiore
The Bronx, New York, United States
Duke University Hospital
Durham, North Carolina, United States
Akron Children's Hospital
Akron, Ohio, United States
Tod Children's Hospital
Youngstown, Ohio, United States
Milton S Hershey Medical Center
Hershey, Pennsylvania, United States
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, United States
Vanderbilt University Medical
Nashville, Tennessee, United States
Children's Cancer and Blood Disorders Center
San Antonio, Texas, United States
Methodist Hospital
San Antonio, Texas, United States
Sacred Heart Medical Center
Spokane, Washington, United States
West Virginia University
Morgantown, West Virginia, United States
Childrens Hospital of Wisconsin
Milwaukee, Wisconsin, United States
San Jorge Childrens Medical
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C8278b/202/BP/US-CA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.